The role of PET/CT for evaluating breast cancer
- PMID: 17923786
- PMCID: PMC2626817
- DOI: 10.3348/kjr.2007.8.5.429
The role of PET/CT for evaluating breast cancer
Abstract
Positron emission tomography combined with computed tomography (PET/CT) has been receiving increasing attention during the recent years for making the diagnosis, for determining the staging and for the follow-up of various malignancies. The PET/CT findings of 58 breast cancer patients (age range: 34-79 years old, mean age: 50 years) were retrospectively compared with the PET or CT scans alone. PET/CT was found to be better than PET or CT alone for detecting small tumors or multiple metastases, for accurately localizing lymph node metastasis and for monitoring the response to chemotherapy in breast cancer patients.
Figures
References
-
- Minn H, Soini I. F-18 fluorodeoxyglucose scintigraphy in diagnosis and follow up of treatment in advanced breast cancer. Am J Clin Pathol. 1989;91:535–541. - PubMed
-
- Kubota K, Matsuzawa T, Amemiya A, Kondo M, Fujiwara T, Watanuki S, et al. Imaging of breast cancer with F-18 fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr. 1989;13:1097–1098. - PubMed
-
- Wahl RL, Cody RL, Hutchins GD, Mudgett EE. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1991;179:765–770. - PubMed
-
- Kostakoglu L, Goldsmith SJ. 18F-FDG PET evaluation of the response to therapy for lymphoma and for breast, lung, and colorectal carcinoma. J Nucl Med. 2003;44:224–239. - PubMed
-
- Beyer T, Townsend DW, Brun T, Kinahan PE, Charron M, Roddy R, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med. 2000;41:1369–1379. - PubMed
